Cambridge university spin-out HutanBio Ltd bags £2.25m seed financing
British-Malasian marine algae biofuel start-up HutanBio has secured an £2.25m seed investment to produce carbon negative biodiesel in brackish water.<br /><br /><br />
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1247 entries already.
British-Malasian marine algae biofuel start-up HutanBio has secured an £2.25m seed investment to produce carbon negative biodiesel in brackish water.<br /><br /><br />
The European Parliament adopted its position for negotiations with Member States on the Commission's proposal on new genomic techniques (NGTs) in favour for using CRISPR/Cas as a new but now […]
After two "Yes"-votes in the European Parliament’s AGRI and ENVI committees, MEPs confirmed the European Commissions draft Regulation on New Genomic Technologies in plant breeding.<br /> <br /><br /> <br /><br […]
Jazz Pharmaceuticals plc has entered an agreement with Redx Pharma to acquire commercialisation rights to Redx KRAS blockers, which include G12D selective and pan-KRAS molecules.<br /><br />
Jazz Pharmaceuticals plc has entered an agreement with Redx Pharma to acquire commercialisation rights to Redx KRAS blockers, which include G12D selective and pan-KRAS molecules.<br /><br />
Spanish Food tech Start-up Heura Foods secures €40m in Series B financing round to expand product distribution.<br /><br /><br />
Spanish Food tech Start-up Heüra Foods secures €40m in Series B financing round to expand product distribution.<br /><br /><br />
Biovian and 3P Biopharmaceuticals have created a new pan-European CDMO, dubbed 3PBIOVIAN. <h2></h2> <h2></h2>
Enterprise Therapeutics Ltd. has raised £26m for the Phase IIa trial of ETD001, a novel cystic fibrosis treatment, with investment led by Panakes Partners and participation from existing investors.
AVT03, a biosimilar candidate for osteoporosis treatment, showed promise in treating bone illnesses, according to results from a pharmacokinetic study by Alvotech SA.